Prucalopride for constipation

Bibliography

• Higgins P, Johanson J. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-9
   PubMed Web of Science ®Google Scholar
• Bharucha A, Camilleri M, Haydock S, Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut 2000;47:667-74
   PubMed Web of Science ®Google Scholar
• Shah N, Chitkara D, Locke G, Ambulatory care for constipation in the United States, 1993 – 2004. Am J Gastroenterol 2008;103:1746-53
   PubMed Web of Science ®Google Scholar
• Choung R, Locke GR, Schleck C, Cumulative incidence of chronic constipation: a population-based study 1988 – 2003. Aliment Pharmacol Ther 2007;26:1521-8
   PubMed Web of Science ®Google Scholar
• Johanson J, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007;25:599-608
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349:1360-8
   PubMed Web of Science ®Google Scholar
• De Maeyer J, Ver Donck L, Heylen L, Schuurkes J. Prucalopride, the first representative of a new generation of highly selective 5-HT4 receptor agonists. UEGW. Paris: UEGF, 2007: OP-E-381
   Google Scholar
• FDA Requires Boxed Warning and Risk Mitigation Strategy for Metoclopramide-Containing Drugs. FDA, Press Announcements. Washington, DC: FDA/News Events, 2009. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149533.htm. [Last accessed 27 September 2009]
   Google Scholar
• FDA Announces Discontinued Marketing of GI Drug, Zelnorm for Safety Reasons. FDA, Press Announcements. Washington, DC: FDA/News Events, 2007. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108879.htm. [Last accessed 27 September 2009]
   Google Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20:99-112
   PubMed Web of Science ®Google Scholar
• Propulsid (cisapride) Dear Healthcare Professional Letter. FDA, Safety Information. Washington, DC: FDA/Safety, 2000. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm175000.htm. [Last accessed 27 September 2009]
   Google Scholar
• Mohammad S, Zhou Z, Gong Q, January C. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997;273:H2534-8
   PubMed Web of Science ®Google Scholar
• Wysowski D, Corken A, Gallo-Torres H, Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-703
   PubMed Web of Science ®Google Scholar
• Johanson J, Drossman D, Panas R, Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008 274:685-96
   Google Scholar
• Johanson J, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008;103:170-7
   PubMed Web of Science ®Google Scholar
• Hegde S, Eglen R. Peripheral 5-HT4 receptors. FASEB J 1996;10:1398-407
   PubMed Web of Science ®Google Scholar
• Foxx-Orenstein A, Kuemmerle J, Grider J. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 1996;111:1281-90
   PubMed Web of Science ®Google Scholar
• Briejer M, Bosmans J, Van Daele P, The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol 2001;423:71-83
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Prins NH, Schuurkes JA, Lefebvre RA. Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: an operational framework to explain and quantify organ-specific behavior. J Pharmacol Exp Ther 2006;317:955-64
   PubMedGoogle Scholar
• Cellek S, Thangiah R, Jarvie EM, Synergy between 5-HT4 receptor activation and acetylcholinesterase inhibition in human colon and rat forestomach. Neurogastroenterol Motil 2008;20:539-45
   PubMed Web of Science ®Google Scholar
• Prins N, Shankley N, Welsh N, An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle. Br J Pharmacol 2000;129:1601-8
   PubMed Web of Science ®Google Scholar
• Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. 5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol 2000;131:927-32
   PubMed Web of Science ®Google Scholar
• Prins N, Van Haselen J, Lefebvre R, Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle. Br J Pharmacol 1999;127:1431-7
   PubMed Web of Science ®Google Scholar
• Leclere PG, Prins NH, Schuurkes JA, Lefebvre RA. 5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol Motil 2005;17:366-75
   PubMed Web of Science ®Google Scholar
• Cellek S, John A, Thangiah R, 5-HT4 receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. Neurogastroenterol Motil 2006;18:853-61
   PubMed Web of Science ®Google Scholar
• Prins N, van Der Grijn A, Lefebvre R, 5-HT(4) receptors mediating enhancement of contractility in canine stomach; an in vitro and in vivo study. Br J Pharmacol 2001;132:1941-7
   PubMed Web of Science ®Google Scholar
• Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001;13:465-72
   PubMed Web of Science ®Google Scholar
• Karaus M, Sarna S. Giant migrating contractions during defecation in the dog colon. Gastroenterology 1987;92:925-33
   PubMed Web of Science ®Google Scholar
• Bassotti G, Chiarioni G, Vantini I, Anorectal manometric abnormalities and colonic propulsive impairment in patients with severe chronic idiopathic constipation. Dig Dis Sci 1994;39:1558-64
   PubMedGoogle Scholar
• Briejer M, Engelen M, Jacobs J, R093877 enhances defecation frequency in conscious cats. Gastroenterology 1997;112:A705
   Google Scholar
• Qi H, Luo J, Liu X. Effect of enterokinetic prucalopride on intestinal motility in fast rats. World J Gastroenterol 2003;9:2065-7
   PubMed Web of Science ®Google Scholar
• De Winter B, Boeckxstaens G, De Man J, Effect of different prokinetic agents and a novel enterokinetic agent on postoperative ileus in rats. Gut 1999;45:713-18
   PubMed Web of Science ®Google Scholar
• Briejer M, Meulemans A, Wellens A, Schuurkens J. R093877 dose-dependently accelerates gastric emptying in conscious dogs. Gastroenterology 1997;112:A705
   Web of Science ®Google Scholar
• Van de Velde V, Ausma J, Vandeplassche L. Pharmacokinetics of prucalopride (Resolor®) in man. Gut 2008;57:A282
   Google Scholar
• Van de Velde V, Ausma J, Vandeplassche L. Food does not affect the oral bioavailability of prucalopride. Gastroenterology 2008;134:A547
   Google Scholar
• Investigator's brochure on prucalopride. Movetis NV, Turnhout, Belgium
   Google Scholar
• Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682-6
   PubMed Web of Science ®Google Scholar
• Vandeplassche G, Crabbé R, De Smedt H, A placebo-controlled study to evaluate the effects of R093877 on bowel habit, safety and tolerability in healthy volunteers. Gastroenterology 1997;112:A843
   Google Scholar
• Hagger R, Benson M, Lloyd R, A placebo-controlled study to evaluate the effect on colonic transit of R093877 in healthy volunteers. Gastroenterology 1998;144:A759
   Google Scholar
• Emmanuel A, Kamm M, Roy A, Antonelli K. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 1998;42:511-16
   PubMed Web of Science ®Google Scholar
• Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999;13:1493-7
   PubMed Web of Science ®Google Scholar
• De Schryver AM, Andriesse GI, Samsom M, The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002;16:603-12
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354-60
   PubMed Web of Science ®Google Scholar
• Sloots CE, Poen AC, Kerstens R, Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16:759-67
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16:1347-56
   PubMed Web of Science ®Google Scholar
• Coremans G, Kerstens R, De Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003;67:82-9
   PubMed Web of Science ®Google Scholar
• Nichols T, Beyens G, Ausma J, A double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of prucalopride in patients with chronic constipation. UEGW. Vienna 2008:P0894
   Google Scholar
• Miner PJ, Nichols T, Silvers D, The efficacy and safety of prucalopride in patients with chronic constipation. Gastroenterology 1999;116:A1043
   PubMed Web of Science ®Google Scholar
• Felt-Bersma R, Bouchoucha M, Wurzer H, Effects of a new enterokinetic drug, prucalopride, on symptoms of patients with chronic constipation: a double-blind, placebo-controlled, multicenter study in Europe. Gastroenterology 1999;116:A1043
   PubMed Web of Science ®Google Scholar
• Winter H, Ausma J, Vandeplassche L. An open label follow-up study of prucalopride solution in pediatric subjects with functional fecal retention. Gastroenterology 2009;136:A129
   Web of Science ®Google Scholar
• Moulin D, Rykx A, Kerstens R, Vandeplassche L. Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor®) in patients with opioid-induced constipation. Gastroenterology 2008;134:A92
   Google Scholar
• Schuurkes J, Meulemans A, Briejer M, The enterokinetic R093877 normalizes opioid-delayed fecal pellet propulsion in the isolated guinea-pig distal colon. Gastroenterology 1998;114:A835
   Google Scholar
• Krogh K, Jensen MB, Gandrup P, Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 2002;37:431-6
   PubMed Web of Science ®Google Scholar
• Galandiuk S, Beyens G, Ausma J, Vandeplassche L. Evaluation of the efficacy, safety and tolerability of prucalopride (Resolor®) given subcutaneously in patients undergoing elective partial colectomy. Gastroenterology 2008;134:A138
   Google Scholar
• D'Hooghe B, Guillaum D, Medaer R, Treatment of constipation in multiple sclerosis patients: pilot study with the novel enterokinetic prucalopride. Neurogastroenterol Motil 1999;11:A256
   Google Scholar
• Kamm M, Emmanuel A, Kerstens R, Vandeplassche L. Double-blind, placebo-controlled, cross-over, multiple (n = 1) trial to evaluate the effects of prucalopride in patients with chronic intestinal pseudo-obstruction (CIP). UEGW. Vienna 2008:P0900
   Google Scholar
• Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 2002;97:194-7
   PubMedGoogle Scholar
• Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344-54
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009;29:315-28
   PubMed Web of Science ®Google Scholar
• Tack J, van Outryve M, Beyens G, Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009;58:357-65
   PubMed Web of Science ®Google Scholar
• Frank L, Kleinman L, Farup C, Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999;34:870-7
   PubMed Web of Science ®Google Scholar
• Marquis P, De La Loge C, Dubois D, Development and validation of the patient assessment of constipation quality of life questionnaire. Scand J Gastroenterol 2005;40:540-51
   PubMed Web of Science ®Google Scholar
• Johanson JF, Wald A, Tougas G, Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial. Clin Gastroenterol Hepatol 2004;2:796-805
   PubMed Web of Science ®Google Scholar
• Tack J, Middleton S, Horne M, Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:1655-65
   PubMed Web of Science ®Google Scholar
• Müller-Lissner S. Treatment of chronic constipation with cisapride and placebo. Gut 1987;28:1033-8
   PubMed Web of Science ®Google Scholar
• Petticrew M, Rodgers M, Booth A. Effectiveness of laxatives in adults. Qual Health Care 2001;10:268-73
   Google Scholar
• Camilleri M, Beyens G, Kerstens R, Vandeplassche L. Long-term follow-up safety and satisfaction with bowel function in response to oral prucalopride in patients with chronic constipation. Gastroenterology 2009;136:A31
   Web of Science ®Google Scholar
• Tack J, Dubois D, Kerstens R, PAC-QOL results from 3 identical randomized placebo-controlled trials with prucalopride in patients with severe chronic constipation. Gastroenterology 2009;136:A533
   Google Scholar
• Krobert KA, Brattelid T, Levy FO, Kaumann AJ. Prucalopride is a partial agonist through human and porcine atrial 5-HT4 receptors: comparison with recombinant human 5-HT4 splice variants. Naunyn Schmiedebergs Arch Pharmacol 2005;371:473-9
   PubMed Web of Science ®Google Scholar
• De Maeyer J, Straetemans R, Schuurkes J, Lefebvre R. Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development. Br J Pharmacol 2006;147:140-57
   PubMed Web of Science ®Google Scholar
• Bach T, Syversveen T, Kvingedal A, 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch Pharmacol 2001;363:146-60
   PubMed Web of Science ®Google Scholar
• Pau D, Workman AJ, Kane KA, Rankin AC. Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists. J Pharmacol Exp Ther 2005;313:146-53
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Schuurkes JA, Lefebvre RA. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in stomach. Br J Pharmacol 2009;156:362-76
   PubMed Web of Science ®Google Scholar
• Walker B, Singleton C, Bursill J, Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br J Pharmacol 1999;128:444-50
   PubMed Web of Science ®Google Scholar
• Rampe D, Roy M, Dennis A, Brown A. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997;417:28-32
   PubMed Web of Science ®Google Scholar
• Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 2001;299:1007-12
   PubMed Web of Science ®Google Scholar
• Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007;554:98-105
   PubMed Web of Science ®Google Scholar
• Boyce M, Kerstens R, Beyens G, Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trails. Gastroenterology 2009;136:T1265
   Google Scholar
• Camilleri M, Beyens G, Kerstens R, Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256–64
   PubMed Web of Science ®Google Scholar
• Committee for medicinal products for human use: summary of positive opinion for Resolor. EMEA Committee for medicinal products for human use. London: EMEA/Pre-Authorisation Evaluation of Medicines for Human Use, 2009. Available from: http://www.emea.europa.eu/pdfs/human/opinion/Resolor_44905009en.pdf. [Last accessed 27 September 2009]
   Google Scholar